Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (223)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (636)
  2. Solid Tumor Oncology Division (636)
  3. Thoracic Oncology (636)
  4. Department of Pathology and Laboratory Medicine (208)
  5. GSK Faculty (189)
  6. Human Oncology and Pathogenesis Program (158)

More Groups

People
  1. Marc Ladanyi (122)
  2. Mark Kris (90)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (20)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (636)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition
    Meeting Abstract

    Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Immunotherapy for non-small cell lung cancers (NSCLC) with oncogenic driver mutations: New results from the global IMMUNOTARGET registry
    Meeting Abstract

    Gautschi, O.; Drilon, A.; Milia, J.; Lusque, A.; Mhanna, L.; Li, B.; Sabari, J.; Cortot, A.; Besse, B.; Mezquita, L.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Updated antitumor activity of crizotinib in patients with MET exon 14-altered advanced non-small cell lung cancer
    Meeting Abstract

    Drilon, A.; Clark, J.; Weiss, J.; Ou, S.; Camidge, D. R.; Solomon, B.; Otterson, G.; Villaruz, L.; Riely, G.; Heist, R.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical activity of LOXO-292, a highly selective RET inhibitor, in patients with RET fusion+ non-small cell lung cancer
    Meeting Abstract

    Oxnard, G.; Subbiah, V.; Park, K.; Bauer, T.; Wirth, L.; Velcheti, V.; Shah, M.; Besse, B.; Boni, V.; Reckamp, K.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Doebele, R.; Ahn, M.; Siena, S.; Drilon, A.; Krebs, M.; Lin, C.; De Braud, F.; John, T.; Tan, D.; Seto, T.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Safety and preliminary clinical activity of ropotrectinib ( TPX-0005), a ROS1/TRK/ALK inhibitor, in advanced ROS1 fusion-positive NSCLC
    Meeting Abstract

    Lin, J.; Kim, D.; Drilon, A.; Doebele, R.; Lee, J.; Zhu, V.; Ahn, M.; Lim, J.; Stopatschinskaja, S.; Cui, J. J.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers
    Meeting Abstract

    Drilon, A. E.; Subbiah, V.; Oxnard, G. R.; Bauer, T. M.; Velcheti, V.; Lakhani, N. J.; Besse, B.; Park, K.; Patel, J. D.; Cabanillas, M. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations
    Meeting Abstract

    Mhanna, L.; Milia, J.; Lusque, A.; Couraud, S.; Mascaux, C.; Veillon, R.; Frueh, M.; Moro-Sibilot, D.; Lattuca-Truc, M.; Tomasini, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Entrectinib: An orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
    Journal Article

    Liu, D.; Offin, M.; Harnicar, S.; Li, B. T.; Drilon, A.
    Therapeutics and Clinical Risk Management (2018)

    Fulltext@MSK | Save
  • Tumor-agnostic drug development
    Journal Article

    Offin, M.; Liu, D.; Drilon, A.
    American Society of Clinical Oncology Educational Book (2018)

    Fulltext@MSK | Save